ES2661838T5 - Formas de dosificación farmacéuticas intranasales que comprenden naloxona - Google Patents

Formas de dosificación farmacéuticas intranasales que comprenden naloxona Download PDF

Info

Publication number
ES2661838T5
ES2661838T5 ES12721507T ES12721507T ES2661838T5 ES 2661838 T5 ES2661838 T5 ES 2661838T5 ES 12721507 T ES12721507 T ES 12721507T ES 12721507 T ES12721507 T ES 12721507T ES 2661838 T5 ES2661838 T5 ES 2661838T5
Authority
ES
Spain
Prior art keywords
naloxone
administration
dosage form
amount
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12721507T
Other languages
English (en)
Spanish (es)
Other versions
ES2661838T3 (es
Inventor
John Strang
Alexander Oksche
Stephen Harris
Kevin Smith
Lucie Helene Jeanne Mottier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44658496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2661838(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Application granted granted Critical
Publication of ES2661838T3 publication Critical patent/ES2661838T3/es
Publication of ES2661838T5 publication Critical patent/ES2661838T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Addiction (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES12721507T 2011-05-13 2012-05-11 Formas de dosificación farmacéuticas intranasales que comprenden naloxona Active ES2661838T5 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11166076 2011-05-13
EP11166076 2011-05-13
PCT/EP2012/058792 WO2012156317A2 (en) 2011-05-13 2012-05-11 Intranasal pharmaceutical dosage forms comprising naloxone

Publications (2)

Publication Number Publication Date
ES2661838T3 ES2661838T3 (es) 2018-04-04
ES2661838T5 true ES2661838T5 (es) 2021-11-18

Family

ID=44658496

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12721507T Active ES2661838T5 (es) 2011-05-13 2012-05-11 Formas de dosificación farmacéuticas intranasales que comprenden naloxona

Country Status (37)

Country Link
US (7) US20150018379A1 (enExample)
EP (2) EP3320893A1 (enExample)
JP (3) JP6110367B2 (enExample)
KR (2) KR101873174B1 (enExample)
CN (2) CN107260672A (enExample)
AR (1) AR086391A1 (enExample)
AT (1) AT16553U1 (enExample)
AU (2) AU2012257785B2 (enExample)
BR (1) BR112013029126A2 (enExample)
CA (1) CA2835940C (enExample)
CO (1) CO6821959A2 (enExample)
CY (1) CY1120399T1 (enExample)
DE (1) DE202012013606U1 (enExample)
DK (2) DK2706982T4 (enExample)
ES (1) ES2661838T5 (enExample)
HK (1) HK1255428A1 (enExample)
HR (1) HRP20180233T1 (enExample)
HU (1) HUE036465T2 (enExample)
IL (1) IL229409B (enExample)
LT (1) LT2706982T (enExample)
ME (1) ME02958B (enExample)
MX (1) MX354249B (enExample)
MY (1) MY194947A (enExample)
NO (1) NO2706982T3 (enExample)
PH (2) PH12013502313A1 (enExample)
PL (1) PL2706982T3 (enExample)
PT (1) PT2706982T (enExample)
RS (1) RS57054B1 (enExample)
RU (2) RU2657441C1 (enExample)
SG (1) SG194927A1 (enExample)
SI (1) SI2706982T1 (enExample)
SM (1) SMT201800105T1 (enExample)
TR (1) TR201802716T4 (enExample)
TW (1) TWI486161B (enExample)
UA (1) UA110974C2 (enExample)
WO (1) WO2012156317A2 (enExample)
ZA (1) ZA201308280B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
NO2706982T3 (enExample) * 2011-05-13 2018-06-02
WO2015095644A1 (en) 2013-12-20 2015-06-25 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
EP3777838A1 (en) * 2014-03-14 2021-02-17 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10722510B2 (en) 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
CA2954637A1 (en) * 2014-07-09 2016-01-14 Opiant Pharmaceuticals, Inc. Co-packaged drug products
US9517307B2 (en) 2014-07-18 2016-12-13 Kaleo, Inc. Devices and methods for delivering opioid antagonists including formulations for naloxone
US11559483B2 (en) * 2015-07-10 2023-01-24 Sanjay Gupta Nasal foam via cribriform plate for medication delivery to the brain and/or body and for nasal moisturization and hygiene
EP3349756A4 (en) * 2015-09-17 2019-05-15 Adapt Pharma Limited NASAL MEDICAMENT PRODUCTS AND METHOD FOR USE THEREOF
US20190209464A1 (en) * 2016-06-24 2019-07-11 Opiant Pharmaceuticals, Inc. Compositions, devices and methods for the treatment of alcohol use disorder
WO2018034920A1 (en) * 2016-08-17 2018-02-22 Insys Development Company, Inc. Liquid naloxone spray
WO2020198327A1 (en) * 2019-03-26 2020-10-01 Pocket Naloxone Corp. Devices and methods for delivering pharmaceutical compositions
EP3946547A4 (en) 2019-03-26 2023-01-18 Pocket Naloxone Corp. DEVICES AND METHODS FOR DELIVERING PHARMACEUTICAL COMPOSITIONS
US10653690B1 (en) * 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
US10729687B1 (en) 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
WO2021222545A1 (en) * 2020-04-29 2021-11-04 The Texas A&M University System Naloxone nanoparticle compositions and methods thereof
HRP20221361T1 (hr) 2020-05-18 2023-01-06 Orexo Ab Novi farmaceutski sastav za davanje lijeka
US11278709B1 (en) 2021-03-12 2022-03-22 Pocket Naloxone Corp. Drug delivery device and methods for using same
WO2023014906A1 (en) 2021-08-04 2023-02-09 Opiant Pharmaceuticals, Inc. Compositions and methods for the treatment of opioid overdose
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
WO2023094826A1 (en) 2021-11-25 2023-06-01 Orexo Ab Pharmaceutical composition comprising adrenaline

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
US5866154A (en) * 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
US6608073B1 (en) 1998-10-14 2003-08-19 New Millennium Pharmaceutical Research, Inc. Intranasal codeine for the rapid suppression of cough and rapid relief of pain
GB9908921D0 (en) * 1999-04-19 1999-06-16 Britannia Pharmaceuticals Ltd Spray dispenser for opiod antagonists
SI20850A (sl) 1999-06-16 2002-10-31 Nastech Pharmaceutical Co., Inc. Farmacevtske formulacije in postopki, ki obsegajo intranazalni morfin
GB9924797D0 (en) 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
US6284765B1 (en) 2000-04-27 2001-09-04 The University Of North Texas Health Science Center At Fort Worth (+) naloxone and epinephrine combination therapy
WO2002011778A1 (en) * 2000-05-10 2002-02-14 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
AU2001281746C1 (en) * 2000-07-31 2010-09-09 ISTITUTO GENTILI S.r.l. Fentanyl composition for nasal administration
DE10064219B9 (de) 2000-12-22 2009-02-12 Nasalis Pain Relief International Gmbh Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US20060110333A1 (en) 2002-07-11 2006-05-25 Taiho Pharmaceutical Co., Ltd. Composition for nasal absorption
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
CN1575795A (zh) 2003-06-25 2005-02-09 中国人民解放军军事医学科学院毒物药物研究所 盐酸纳洛酮鼻腔喷雾剂
GB2403711A (en) * 2003-07-07 2005-01-12 Gw Pharma Ltd Drug dispenser with controlled access
GB0400804D0 (en) 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
CN1726915B (zh) * 2004-07-27 2013-04-24 中国人民解放军军事医学科学院毒物药物研究所 盐酸纳洛酮鼻腔给药系统或组合物及其制备方法
US8673360B2 (en) 2004-08-10 2014-03-18 Shin Nippon Biomedical Laboratories, Ltd. Compositions that enable rapid-acting and highly absorptive intranasal administration
CN100524037C (zh) * 2004-11-09 2009-08-05 皇家飞利浦电子股份有限公司 空间光调制器阵列和制造空间光调制器设备的方法
AU2005322305B2 (en) * 2004-12-23 2010-09-16 Roxro Pharma, Inc. Therapeutic compositions for intranasal administration of ketorolac
US8911751B2 (en) 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
US20070212307A1 (en) * 2006-02-10 2007-09-13 Daniel Wermeling Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
RU2344822C2 (ru) * 2006-04-05 2009-01-27 Алексей Валентинович Надеждин Способ лечения героиновой наркомании
EP2116264B1 (en) 2006-12-26 2017-09-27 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
EP3150230A1 (en) * 2007-01-19 2017-04-05 Hananja Ehf Methods and compositions for the delivery of a therapeutic agent
WO2009040595A1 (en) 2007-09-28 2009-04-02 Wockhardt Research Centre Multi-dose pharmaceutical composition of analgesic for nasal administration
NO2706982T3 (enExample) * 2011-05-13 2018-06-02
WO2015095644A1 (en) 2013-12-20 2015-06-25 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
EP3777838A1 (en) 2014-03-14 2021-02-17 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US10617686B2 (en) 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray

Also Published As

Publication number Publication date
EP3320893A1 (en) 2018-05-16
KR20140007482A (ko) 2014-01-17
AU2016204880A1 (en) 2016-07-28
US20190374464A1 (en) 2019-12-12
NO2706982T3 (enExample) 2018-06-02
PL2706982T3 (pl) 2018-07-31
KR101873174B1 (ko) 2018-06-29
EP2706982B2 (en) 2021-03-10
AU2016204880B2 (en) 2017-11-23
EP2706982B1 (en) 2018-01-03
JP2016128453A (ja) 2016-07-14
CN103764119A (zh) 2014-04-30
DE202012013606U1 (de) 2018-04-18
RS57054B1 (sr) 2018-05-31
PH12016501342B1 (en) 2018-06-11
TWI486161B (zh) 2015-06-01
US20240082149A1 (en) 2024-03-14
RU2657441C1 (ru) 2018-06-13
CN107260672A (zh) 2017-10-20
CY1120399T1 (el) 2019-07-10
TR201802716T4 (tr) 2018-03-21
US20170231904A1 (en) 2017-08-17
DK2706982T4 (da) 2021-05-10
LT2706982T (lt) 2018-05-25
JP2018150336A (ja) 2018-09-27
IL229409B (en) 2020-10-29
DK2706982T3 (en) 2018-03-12
US20150126540A1 (en) 2015-05-07
EP2706982A2 (en) 2014-03-19
UA110974C2 (uk) 2016-03-10
RU2587051C2 (ru) 2016-06-10
MX354249B (es) 2018-02-20
DK201800034U1 (da) 2018-05-25
JP6110367B2 (ja) 2017-04-05
US20170304192A1 (en) 2017-10-26
ME02958B (me) 2018-07-20
HK1255428A1 (en) 2019-08-16
KR20170010078A (ko) 2017-01-25
ZA201308280B (en) 2014-07-30
CA2835940A1 (en) 2012-11-22
RU2013155479A (ru) 2015-06-20
WO2012156317A2 (en) 2012-11-22
AU2012257785B2 (en) 2016-04-14
SMT201800105T1 (it) 2018-05-02
HRP20180233T1 (hr) 2018-06-01
BR112013029126A2 (pt) 2017-02-07
AU2012257785A1 (en) 2013-11-28
US11806428B2 (en) 2023-11-07
US20210338574A1 (en) 2021-11-04
PT2706982T (pt) 2018-03-08
MX2013013276A (es) 2014-08-07
WO2012156317A3 (en) 2013-05-10
TW201311244A (zh) 2013-03-16
US20150018379A1 (en) 2015-01-15
AT16553U1 (de) 2020-01-15
CA2835940C (en) 2020-08-04
HUE036465T2 (hu) 2018-07-30
NZ705933A (en) 2016-07-29
CO6821959A2 (es) 2013-12-31
NZ617442A (en) 2015-03-27
AR086391A1 (es) 2013-12-11
JP2014513683A (ja) 2014-06-05
ES2661838T3 (es) 2018-04-04
MY194947A (en) 2022-12-27
SI2706982T1 (en) 2018-05-31
US12458591B2 (en) 2025-11-04
SG194927A1 (en) 2013-12-30
PH12016501342A1 (en) 2018-06-11
US11020343B2 (en) 2021-06-01
PH12013502313A1 (en) 2022-04-08
KR101698182B1 (ko) 2017-01-19
IL229409A0 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
ES2661838T5 (es) Formas de dosificación farmacéuticas intranasales que comprenden naloxona
ES2631504A2 (es) Medicamentos de administración nasal y métodos para su uso
HK1193762A (en) Intranasal pharmaceutical dosage forms comprising naloxone
HK1193762B (en) Intranasal pharmaceutical dosage forms comprising naloxone
NZ617442B2 (en) Intranasal pharmaceutical dosage forms comprising naloxone
NZ705933B2 (en) Intranasal pharmaceutical dosage forms comprising naloxone